We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+16.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.73B
AUM Growth
+$239M
Cap. Flow
+$39.4M
Cap. Flow %
2.27%
Top 10 Hldgs %
27.21%
Holding
142
New
9
Increased
33
Reduced
17
Closed
2

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$27.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$20.9M
3
PCRX icon
Pacira BioSciences
PCRX
+$12.4M
4
AFAM
Almost Family Inc
AFAM
+$10.8M
5
OBSV
ObsEva SA Ordinary Shares
OBSV
+$10.3M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$27.7M
2
TSRO
TESARO, Inc.
TSRO
+$22.6M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$12.3M
4
MEDP icon
Medpace
MEDP
+$4.87M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$3.11M

Sector Composition

Rank Sector Weight
1 Healthcare 82.21%
2 Financials 2.45%
3 Consumer Discretionary 0.63%
4 Industrials 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
51
BioMarin Pharmaceuticals
BMRN
$12.3B
$11M 0.63%
125,000
– –
AFAM
52
DELISTED
Almost Family Inc
AFAM
$10.9M 0.63%
+225,000
New +$10.8M
RARE icon
53
Ultragenyx Pharmaceutical
RARE
$2.55B
$10.8M 0.62%
159,750
– –
AVXS
54
DELISTED
AveXis, Inc. Common Stock
AVXS
$10.6M 0.61%
140,000
– –
PTHN
55
DELISTED
Patheon N.V.
PTHN
$10.5M 0.61%
400,000
– –
PRTK
56
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$10.1M 0.58%
525,500
– –
ASMB icon
57
Assembly Biosciences
ASMB
$529M
$9.94M 0.57%
32,500
– –
VRTX icon
58
Vertex Pharmaceuticals
VRTX
$126B
$9.9M 0.57%
90,500
+750
+0.8% +$66K
EPZM
59
DELISTED
Epizyme, Inc
EPZM
$9.78M 0.56%
570,000
– –
ONC
60
BeOne Medicines Ltd
ONC
$38.7B
$9.7M 0.56%
265,000
– –
MRUS
61
DELISTED
Merus
MRUS
$9.38M 0.54%
384,548
-15,452
-4% -$395K
ASND icon
62
Ascendis Pharma A/S
ASND
$16.8B
$9.1M 0.53%
325,000
– –
EVHC
63
DELISTED
Envision Healthcare Holdings Inc
EVHC
$8.89M 0.51%
145,000
– –
CRVS icon
64
Corvus Pharmaceuticals
CRVS
$1.17B
$8.78M 0.51%
422,600
-27,400
-6% -$429K
OBSV
65
DELISTED
ObsEva SA Ordinary Shares
OBSV
$8.73M 0.5%
+838,634
New +$10.3M
BOLD
66
DELISTED
Audentes Therapeutics, Inc
BOLD
$8.52M 0.49%
500,000
+15,000
+3% +$243K
INSM icon
67
Insmed
INSM
$28.6B
$8.2M 0.47%
468,000
– –
EXAS
68
DELISTED
Exact Sciences
EXAS
$7.97M 0.46%
337,500
-113,400
-25% -$2.25M
LOXO
69
DELISTED
Loxo Oncology, Inc
LOXO
$7.62M 0.44%
+181,000
New +$7.45M
SRGA
70
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$7.44M 0.43%
62,000
– –
CLSD
71
DELISTED
Clearside Biomedical
CLSD
$7.42M 0.43%
62,333
– –
TVTX icon
72
Travere Therapeutics
TVTX
$5.78B
$7.38M 0.43%
400,000
-122,000
-23% -$2.39M
ALKS icon
73
Alkermes
ALKS
$8.25B
$7.31M 0.42%
125,000
– –
ATHN
74
DELISTED
Athenahealth, Inc.
ATHN
$7.07M 0.41%
62,750
– –
TTPH
75
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$6.42M 0.37%
34,900
– –
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Rock Springs Capital Management held 142 positions worth $1.73B, up 16% from $1.49B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management's Q1 2017 filing shows 9 new, 33 increased, 17 reduced and 2 closed positions. Its largest new stake was Humana: 132,500 shares worth $27.3M. The largest sale was Aetna Inc, an estimated $27.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 81% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q1 2017 buy was Humana: 132,500 shares worth $27.3M.
  • Rock Springs Capital Management added most to Pacira BioSciences in Q1 2017, an estimated $12.4M increase.
  • Rock Springs Capital Management's biggest Q1 2017 reduction was Aetna Inc, cutting an estimated $27.7M.
  • Rock Springs Capital Management fully exited Medpace in Q1 2017, selling an estimated $4.87M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $1.73B portfolio in Q1 2017.
  • Rock Springs Capital Management opened 9 new positions and closed 2 in Q1 2017.
  • Rock Springs Capital Management's portfolio value rose 16% quarter-over-quarter to $1.73B.

Based on Rock Springs Capital Management's 13F filing for Q1 2017, filed 15 May 2017.